Vlachostergios, Panagiotis J

Publications

Sort by

Co-Author Network

selected publications

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 158
Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature reviews. Clinical oncology. 2018 Information Resource GET IT
Times cited: 18
A critical review on ramucirumab in the treatment of advanced urothelial cancer. Future oncology (London, England). 2017 Information Resource GET IT
Times cited: 4
Emerging Variants of Castration-Resistant Prostate Cancer. Current oncology reports. 2017 Information Resource GET IT
Times cited: 148
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Times cited: 3
Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational andrology and urology. 2017 Editorial Article GET IT
Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. Expert opinion on biological therapy. 2016 Information Resource GET IT
Times cited: 3
Dual light chain extramedullary myeloma presenting with mediastinal lymphadenopathy and lytic bone lesions. 2016 GET IT
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in cancer biology. 2015 Information Resource GET IT
Times cited: 274
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives. World journal of gastrointestinal oncology. 2015 Review GET IT
Times cited: 34
GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015 Letter GET IT
Acute renal infarction associated with homozygous methylenetetrahydrofolate reductase mutation C677T and IgA beta-2-glycoprotein antibodies. 2015 GET IT
Times cited: 6
Feasibility of energy medicine in a community teaching hospital: an exploratory case series. Journal of alternative and complementary medicine (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 2
Composite angioimmunoblastic T-cell and diffuse large B-cell lymphoma. 2015 GET IT
Times cited: 2
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Seminars in cancer biology. 2015 Review GET IT
Times cited: 579
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Frontiers in oncology. 2015 Review GET IT
Times cited: 56
Saddle pulmonary embolism as the initial manifestation of pancreatic cancer. 2015 GET IT
Elevated lactic acid is a negative prognostic factor in metastatic lung cancer. Cancer biomarkers : section A of Disease markers. 2015 Academic Article GET IT
Times cited: 37
Angiomyolipomas, renal cell carcinomas and pulmonary lymphangioleiomyomatosis. Journal of clinical and diagnostic research : JCDR. 2014 Academic Article GET IT
Bevacizumab in advanced cervical cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014 Letter GET IT
Common hepatic duct stricture: are lithiasis and negative brush cytology enough to rule out Klatskin tumor? 2014 GET IT
Bone metastases and hypercalcaemia from cutaneous squamous cell carcinoma. 2014 GET IT
Times cited: 2
Efficacy of zibotentan in colorectal cancer--letter. Molecular cancer therapeutics. 2014 Letter GET IT
The shaping of invasive glioma phenotype by the ubiquitin-proteasome system. Cell communication & adhesion. 2013 Review GET IT
Times cited: 3
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis. Archives of medical science : AMS. 2013 Academic Article GET IT
Times cited: 14
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. Cell biology and toxicology. 2013 Review GET IT
Times cited: 9
The role of ubiquitin-proteasome system in glioma survival and growth. Growth factors (Chur, Switzerland). 2013 Review GET IT
Times cited: 8
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Investigational new drugs. 2013 Academic Article GET IT
Times cited: 29
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53. Neurological research. 2013 Academic Article GET IT
Times cited: 14
The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?. Journal of cell communication and signaling. 2013 Academic Article GET IT
Times cited: 15
Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013 Academic Article GET IT
Times cited: 9
Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cellular and molecular neurobiology. 2013 Academic Article GET IT
Times cited: 19
Hashimoto's Thyroiditis and Kikuchi's Disease: Presentation of a Case and Review of the Literature. Case reports in otolaryngology. 2012 Academic Article GET IT
The ubiquitin-proteasome system in glioma cell cycle control. Cell division. 2012 Academic Article GET IT
Times cited: 22
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells. Cancer cell international. 2012 Academic Article GET IT
Times cited: 5
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy. Prostate cancer. 2012 Academic Article GET IT
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung cancer (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 47
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer. Biomolecules. 2012 Academic Article GET IT
Times cited: 9
Selecting for predisposition to cancer cachexia. EMBO molecular medicine. 2012 Comment GET IT
Times cited: 1
Basic Concepts in Metastatic Cardiac Disease. Cardiology research. 2012 Review GET IT
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. International journal of urology : official journal of the Japanese Urological Association. 2012 Academic Article GET IT
Times cited: 12
CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy. Urologia internationalis. 2012 Academic Article GET IT
Times cited: 12
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. Journal of negative results in biomedicine. 2012 Academic Article GET IT
Times cited: 10
Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?. World journal of experimental medicine. 2011 Review GET IT
Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. Nutrition and cancer. 2011 Academic Article GET IT
Times cited: 17
Pulmonary and cutaneous nodules in an immunocompromised patient. 2011 GET IT
Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology. 2011 Academic Article GET IT
Times cited: 21
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. Journal of molecular medicine (Berlin, Germany). 2011 Academic Article GET IT
Times cited: 113
Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate-gene association study in a South-eastern European population. DNA and cell biology. 2011 Academic Article GET IT
Times cited: 21
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer. Pathology oncology research : POR. 2011 Academic Article GET IT
Times cited: 5
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung cancer (Amsterdam, Netherlands). 2011 Academic Article GET IT
Times cited: 56
Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer cell international. 2011 Academic Article GET IT
Times cited: 14
Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer. 2010 GET IT
Times cited: 10
AFP-producing hepatoid adenocarcinoma of the stomach: a case report. Cases journal. 2009 Academic Article GET IT
Times cited: 8
Orbital metastasis of breast carcinoma. 2009 GET IT
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation. Journal of cellular and molecular medicine. 2009 Review GET IT
Times cited: 28
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. Journal of cellular and molecular medicine. 2009 Review GET IT
Times cited: 15

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab awarded by United States Department of Defense Co-Investigator 2020 - 2025
missing activity Co-Investigator 2020 - 2024

more ...

less ...

Background

education and training

Ph.D., University of Thessaly Faculty of Medicine (Greece) 2013
M.D., University of Thessaly Faculty of Medicine (Greece) 2007

Contact

full name

Panagiotis J Vlachostergios

primary email

pjv9003@med.cornell.edu

VIVO Weill Cornell Medical College

Panagiotis J Vlachostergios Clinical Assistant Professor of Medicine (Courtesy)

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email